Table 3 Frequency of promoter hypermethylation in patients with recurrent or non recurrent disease Gene ID % R % NR Overall Talazoparib cell line series P (Total = 31) (Total = 47) (Total = 78) FHIT 38.71 (12/31) 2.13 (1/47) 16.67 (13/78) 3.1E-05 MLH1 25.81 (8/31) 2.13 (1/47) 11.54 (9/78) 0.002 ATM 22.58 (7/31) 2.13 (1/47) 10.26 (8/78) 0.006 TP73 35.48 (11/31) 12.77 (6/47) 21.79 (17/78) 0.025
BRCA1 9.68 (3/31) 0.00 (0/47) 3.85 (3/78) 0.059 CHFR 29.03 (9/31) 10.64 (5/47) 17.95 (14/78) 0.068 IGSF4 12.90 (4/31) 2.13 (1/47) 6.41 (5/78) 0.078 ESR1 70.97 (22/31) 85.11 (40/47) 79.49 (62/78) 0.158 DAPK1 22.58 (7/31) 10.64 (5/47) 15.38 (12/78) 0.203 CDKN2B 45.16 (14/31) 29.79 (14/47) 35.90 (28/78) 0.228 RASSF1 CpG1 41.94 (13/31) 29.79 (14/47) 34.62 (27/78)
0.333 RASSF1 CpG2 12.90 (4/31) 6.38 (3/47) 8.97 (7/78) 0.427 HIC1 16.13 (5/31) 8.51 (4/47) 11.54 (9/78) 0.471 CDKN2A 22.58 (7/31) 14.89 (7/47) 17.95 (14/78) 0.548 CASP8 6.45 (2/31) 2.13 (1/47) 3.85 (3/78) 0.560 CDH13 80.65 (25/31) Osimertinib manufacturer 74.47 (35/47) 76.92 (60/78) 0.592 CD44 3.23 (1/31) 8.51 (4/47) 6.41 (5/78) 0.643 BRCA2 12.90 (4/31) 8.51 (4/47) 10.26 (8/78) 0.706 RARB 48.39 (15/31) 44.68 (21/47) 46.15 (36/78) 0.818 APC 45.16 (14/31) 48.94 (23/47) 47.44 (37/78) 0.819 TIMP3 38.71 (12/31) 36.17 (17/47) 37.18 (29/78) 1.000 CDKN1B 9.68 (3/31) 8.51 (4/47) 8.97 (7/78) 1.000 VHL 6.45 (2/31) 6.38 (3/47) 6.41 (5/78) 1.000 PTEN 3.23 (1/31) 4.26 (2/47) 3.85 (3/78) 1.000 Abbreviations: R recurrent disease, NR non recurrent disease. Figure 2 Volcano Plot representing the differences in methylation levels between relapsed and non relapsed samples plotted against
their statistical significance for all gene promoters analyzed. The three promoters displaying Methocarbamol significantly increased methylation levels in R samples (two-tailed T test, P < 0.05) are highlighted in the upper right corner. T-test P values of the comparison between methylation levels in R vs NR samples are shown to the right of the plot. In particular, lower levels of methylation were associated with no recurrence of disease, while substantially higher values were correlated with relapse. Moreover, other genes showed differences in terms of methylation alterations. In particular, higher methylation levels of CDKN2B, RASSF1, CHFR, BRCA2 and IGSF4 were observed in adenomas that recurred. Methylation status phenotype and clinical pathological parameters Taking these data into account, we evaluated the methylation status, determined on the basis of the presence or not of hypermethylation in the most significantly altered gene promoters (Table 4a,b).